Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week High – Here’s What Happened

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $88.49 and last traded at $86.1950, with a volume of 314851 shares trading hands. The stock had previously closed at $83.92.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on DNTH shares. Wells Fargo & Company assumed coverage on Dianthus Therapeutics in a report on Thursday, March 19th. They set an “overweight” rating and a $135.00 target price for the company. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Truist Financial raised their price objective on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Finally, Oppenheimer lifted their price objective on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $117.30.

Dianthus Therapeutics Stock Up 1.7%

The stock has a market capitalization of $3.82 billion, a PE ratio of -20.98 and a beta of 1.22. The stock has a fifty day moving average of $63.15 and a 200-day moving average of $47.62.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. Equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Insider Activity

In other Dianthus Therapeutics news, CAO Edward Carr sold 43,682 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marino Garcia sold 122,918 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The SEC filing for this sale provides additional information. Insiders have sold a total of 314,797 shares of company stock valued at $25,825,163 over the last three months. 8.15% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics in the second quarter valued at $27,000. Parkside Financial Bank & Trust lifted its holdings in Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after buying an additional 540 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics during the 4th quarter worth about $40,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics during the 3rd quarter worth about $64,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after acquiring an additional 3,317 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.